The effect of ischemia/reperfusion on the kidney graft

Current Opinion in Organ Transplantation

Volumn 19, Issue 4, 2014, Pages 395-400

  Menke, Julia ^a   Sollinger, Daniel ^a   Schamberger, Beate ^a   Heemann, Uwe ^b   Lutz, Jens ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Adaptive immune system; Delayed graft function; Fibrosis; Innate immunity; Ischemia reperfusion; Kidney transplantation; microrna; Necroptosis; Rejection

Indexed keywords

EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN BCL 2; RANTES; REACTIVE OXYGEN METABOLITE; SYNAPSIN I; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; ZINC FINGER PROTEIN;

ADAPTIVE IMMUNITY; APOPTOSIS; CELL MEMBRANE; CELL METABOLISM; CELLULAR STRESS RESPONSE; COMPLEMENT SYSTEM; DELAYED GRAFT FUNCTION; DENDRITIC CELL; ENERGY METABOLISM; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; HUMAN; INNATE IMMUNITY; KIDNEY FIBROSIS; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY ISCHEMIA; LYMPHOCYTE; NONHUMAN; POLYMORPHONUCLEAR CELL; REGULATORY T LYMPHOCYTE; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; ANIMAL; GRAFT REJECTION; IMMUNOLOGY; KIDNEY TRANSPLANTATION; PATHOPHYSIOLOGY; T LYMPHOCYTE;

ANIMALS; GRAFT REJECTION; HUMANS; IMMUNITY, INNATE; KIDNEY TRANSPLANTATION; REPERFUSION INJURY; T-LYMPHOCYTES;

EID: 84904169502     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000090     Document Type: Review

References (80)

1. Ponticelli C. Ischaemia-reperfusion injury: a major protagonist in kidney transplantation. Nephrol Dial Transplant 2013; 0:1-8. [Epub ahead of print]
2. Lutz J, Thurmel K, Heemann U. Anti-inflammatory treatment strategies for ischemia/reperfusion injury in transplantation. J Inflamm (Lond) 2010; 7:27.
3. Bonventre JV, Zuk A. Ischemic acute renal failure: an inflammatory disease? Kidney Int 2004; 66:480-485.
4. Kinsey GR, Li L, Okusa MD. Inflammation in acute kidney injury. Nephron Exp Nephrol 2008; 109:e102-e107.
5. Daemen MA, van 't Veer C, Denecker G, et al. Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J Clin Invest 1999; 104:541-549.
6. Linkermann A, Green DR. Necroptosis. N Engl J Med 2014; 370:455-465.
7. Kono H, Nakagawa K, Morita S, et al. Effect of a novel nuclear factor-kappa B activation inhibitor on renal ischemia-reperfusion injury. Transplantation 2013; 96:863-870.
8. Latanich CA, Toledo-Pereyra LH. Searching for NF-kappaB-based treatments of ischemia reperfusion injury. J Invest Surg 2009; 22:301-315.
9. Nurmi A, Lindsberg PJ, Koistinaho M, et al. Nuclear factor-kappaB contributes to infarction after permanent focal ischemia. Stroke 2004; 35:987-991.
10. Nelson PJ, Teixeira MM. Dissection of inflammatory processes using chemokine biology: lessons from clinical models. Immunol Lett 2012; 145:55-61.
11. Fischereder M. Chemokines and chemokine receptors in renal transplantation- from bench to bedside. Acta Physiol Hung 2007; 94:67-81.
12. Fischereder M, Schroppel B. The role of chemokines in acute renal allograft rejection and chronic allograft injury. Front Biosci 2009; 14:1807-1814.
13. Furuichi K, Wada T, Kaneko S, Murphy PM. Roles of chemokines in renal ischemia/reperfusion injury. Front Biosci 2008; 13:4021-4028.
14. Jaswal JS, Gandhi M, Finegan BA, et al. Inhibition of p38 MAPK and AMPK restores adenosine-induced cardioprotection in hearts stressed by antecedent ischemia by altering glucose utilization. Am J Physiol Heart Circ Physiol 2007; 293:H1107-H1114.
15. Cugini D, Azzollini N, Gagliardini E, et al. Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. Kidney Int 2005; 67:1753-1761.
16. Bertini R, Allegretti M, Bizzarri C, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A 2004; 101:11791-11796.
17. Wanderer AA. Ischemic-reperfusion syndromes: biochemical and immunologic rationale for IL-1 targeted therapy. Clin Immunol 2008; 128:127-132.
18. Rusai K, Huang H, Sayed N, et al. Administration of interleukin-1 receptor antagonist ameliorates renal ischemia-reperfusion injury. Transpl Int 2008; 21:572-580.
19. Cursio R, Mari B, Louis K, et al. Rat liver injury after normothermic ischemia is prevented by a phosphinic matrix metalloproteinase inhibitor. FASEB J 2002; 16:93-95.
20. Montaner J, Alvarez-Sabin J, Molina C, et al. Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 2001; 32:1759-1766.
21. Shirahane K, Yamaguchi K, Koga K, et al. Hepatic ischemia/reperfusion injury is prevented by a novel matrix metalloproteinase inhibitor, ONO-4817. Surgery 2006; 139:653-664.
22. Lutz J, Yao Y, Song E, et al. Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats. Transplantation 2005; 79:655-661.
23. Yang L, Humphreys BD, Bonventre JV. Pathophysiology of acute kidney injury to chronic kidney disease: maladaptive repair. Contrib Nephrol 2011; 174:149-155.
24. Kang DH, Kanellis J, Hugo C, et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 2002; 13:806-816.
25. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006; 17:17-25.
26. Kimura S, Asaka M, Atsumi H, et al. Circulating fibrocytes in ischemiareperfusion injury and chronic renal allograft fibrosis. Nephron Clin Pract 2012; 121:c16-c24.
27. Chen YT, Chang FC, Wu CF, et al. Platelet-derived growth factor receptor signaling activates pericyte-myofibroblast transition in obstructive and postischemic kidney fibrosis. Kidney Int 2011; 80:1170-1181.
28. Forbes JM, Leaker B, Hewitson TD, et al. Macrophage and myofibroblast involvement in ischemic acute renal failure is attenuated by endothelin receptor antagonists. Kidney Int 1999; 55:198-208.
29. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004; 15:1-12.
30. Humphreys BD, Xu F, Sabbisetti V, et al. Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis. J Clin Invest 2013; 123:4023-4035.
31. Ucero AC, Benito-Martin A, Fuentes-Calvo I, et al. TNF-related weak inducer of apoptosis (TWEAK) promotes kidney fibrosis and Ras-dependent proliferation of cultured renal fibroblast. Biochim Biophys Acta 2013; 1832:1744-1755.
32. Tang J, Liu N, Tolbert E, et al. Sustained activation of EGFR triggers renal fibrogenesis after acute kidney injury. Am J Pathol 2013; 183:160-172.
33. Bitzer M, Ben-Dov IZ, Thum T. Microparticles and microRNAs of endothelial progenitor cells ameliorate acute kidney injury. Kidney Int 2012; 82:375-377.
34. Lorenzen JM, Batkai S, Thum T. Regulation of cardiac and renal ischemiareperfusion injury by microRNAs. Free Radic Biol Med 2013; 64:78-84.
35. Godwin JG, Ge X, Stephan K, et al. Identification of a microRNA signature of renal ischemia reperfusion injury. Proc Natl Acad Sci U S A 2010; 107:14339-14344.
36. Aguado-Fraile E, Ramos E, Saenz-Morales D, et al. miR-127 protects proximal tubule cells against ischemia/reperfusion: identification of kinesin family member 3B as miR-127 target. PLoS One 2012; 7:e44305.
37. Cantaluppi V, Gatti S, Medica D, et al. Microvesicles derived from endothelial progenitor cells protect the kidney from ischemia-reperfusion injury by micro- RNA-dependent reprogramming of resident renal cells. Kidney Int 2012; 82:412-427.
38. Lemos FB, Ijzermans JN, Zondervan PE, et al. Differential expression of heme oxygenase-1 and vascular endothelial growth factor in cadaveric and living donor kidneys after ischemia-reperfusion. J Am Soc Nephrol 2003; 14:3278-3287.
39. Boone DL, Turer EE, Lee EG, et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004; 5:1052-1060.
40. Coornaert B, Carpentier I, Beyaert R. A20: central gatekeeper in inflammation and immunity. J Biol Chem 2009; 284:8217-8221.
41. Lutz J, Luong le A, Strobl M, et al. The A20 gene protects kidneys from ischaemia/reperfusion injury by suppressing pro-inflammatory activation. J Mol Med 2008; 86:1329-1339.
42. Bell LM, Leong ML, Kim B, et al. Hyperosmotic stress stimulates promoter activity and regulates cellular utilization of the serum- and glucocorticoidinducible protein kinase (Sgk) by a p38 MAPK-dependent pathway. J Biol Chem 2000; 275:25262-25272.
43. Firestone GL, Giampaolo JR, O'Keeffe BA. Stimulus-dependent regulation of serum and glucocorticoid inducible protein kinase (SGK) transcription, subcellular localization and enzymatic activity. Cell Physiol Biochem 2003; 13:1-12.
44. Leong ML, Maiyar AC, Kim B, et al. Expression of the serum- and glucocorticoid- inducible protein kinase, Sgk, is a cell survival response to multiple types of environmental stress stimuli in mammary epithelial cells. J Biol Chem 2003; 278:5871-5882.
45. Rusai K, Wagner B, Roos M, et al. The serum and glucocorticoid-regulated kinase 1 in hypoxic renal injury. Cell Physiol Biochem 2009; 24:577-584.
46. Arumugam TV, Okun E, Tang SC, et al. Toll-like receptors in ischemiareperfusion injury. Shock 2009; 32:4-16.
47. Kim BS, Lim SW, Li C, et al. Ischemia-reperfusion injury activates innate immunity in rat kidneys. Transplantation 2005; 79:1370-1377.
48. Rusai K, Sollinger D, Baumann M, et al. Lutz Toll-like receptor 2 and 4 in renal ischemia/reperfusion injury. J Ped Nephrol 2009; 25:853-860.
49. Kruger B, Krick S, Dhillon N, et al. Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci U S A 2009; 106:3390-3395.
50. Leemans JC, Stokman G, Claessen N, et al. Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. J Clin Invest 2005; 115:2894-2903.
51. Leventhal JS, Schroppel B. Toll-like receptors in transplantation: sensing and reacting to injury. Kidney Int 2012; 81:826-832.
52. Chen G, Chen S, Chen X. Role of complement and perspectives for intervention in transplantation. Immunobiology 2013; 218:817-827.
53. Damman J, Schuurs TA, Ploeg RJ, Seelen MA. Complement and renal transplantation: from donor to recipient. Transplantation 2008; 85:923- 927.
54. Diepenhorst GM, van Gulik TM, Hack CE. Complement-mediated ischemiareperfusion injury: lessons learned from animal and clinical studies. Ann Surg 2009; 249:889-899.
55. Hepburn NJ, Ruseva MM, Harris CL, Morgan BP. Complement, roles in renal disease and modulation for therapy. Clin Nephrol 2008; 70:357-376.
56. Farrar CA, Asgari E, Schwaeble WJ, Sacks SH. Which pathways trigger the role of complement in ischaemia/reperfusion injury? Front Immunol 2012; 3:341.
57. Sacks SH, Zhou W. The role of complement in the early immune response to transplantation. Nat Rev Immunol 2012; 12:431-442.
58. Zhou W, Farrar CA, Abe K, et al. Predominant role for C5b-9 in renal ischemia/ reperfusion injury. J Clin Invest 2000; 105:1363-1371.
59. Turnberg D, Botto M, Lewis M, et al. CD59a deficiency exacerbates ischemiareperfusion injury in mice. Am J Pathol 2004; 165:825-832.
60. Farrar CA, Zhou W, Lin T, Sacks SH. Local extravascular pool of C3 is a determinant of postischemic acute renal failure. FASEB J 2006; 20:217-226.
61. Naesens M, Li L, Ying L, et al. Expression of complement components differs between kidney allografts from living and deceased donors. J Am Soc Nephrol 2009; 20:1839-1851.
62. Alikhan MA, Ricardo SD. Mononuclear phagocyte system in kidney disease and repair. Nephrology (Carlton) 2013; 18:81-91.
63. Ioannou A, Dalle Lucca J, Tsokos GC. Immunopathogenesis of ischemia/ reperfusion-associated tissue damage. Clin Immunol 2011; 141:3-14.
64. Okusa MD, Li L. Dendritic cells in acute kidney injury: cues from the microenvironment. Trans Am Clin Climatol Assoc 2012; 123:54-62; discussion 62-63.
65. Ozaki KS, Kimura S, Nalesnik MA, et al. The loss of renal dendritic cells and activation of host adaptive immunity are long-term effects of ischemia/reperfusion injury following syngeneic kidney transplantation. Kidney Int 2012; 81:1015-1025.
66. Linfert D, Chowdhry T, Rabb H. Lymphocytes and ischemia-reperfusion injury. Transplant Rev (Orlando) 2009; 23:1-10.
67. Burne MJ, Daniels F, El Ghandour A, et al. Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest 2001; 108:1283-1290.
68. Kinsey GR, Okusa MD. Role of leukocytes in the pathogenesis of acute kidney injury. Crit Care 2012; 16:214.
69. Kinsey GR, Sharma R, Okusa MD. Regulatory T cells in AKI. J Am Soc Nephrol 2013; 24:1720-1726.
70. Kinsey GR, Huang L, Vergis AL, et al. Regulatory T cells contribute to the protective effect of ischemic preconditioning in the kidney. Kidney Int 2010; 77:771-780.
71. Kinsey GR, Sharma R, Huang L, et al. Regulatory T cells suppress innate immunity in kidney ischemia-reperfusion injury. J Am Soc Nephrol 2009; 20:1744-1753.
72. Cooper JE, Wiseman AC. Acute kidney injury in kidney transplantation. Curr Opin Nephrol Hypertens 2013; 22:698-703.
73. Cecka M. Clinical outcome of renal transplantation. Factors influencing patient and graft survival. Surg Clin North Am 1998; 78:133-148.
74. Irish WD, Ilsley JN, Schnitzler MA, et al. A risk prediction model for delayed graft function in the current era of deceased donor renal transplantation. Am J Transplant 2010; 10:2279-2286.
75. Ortiz F, Paavonen T, Tornroth T, et al. Predictors of renal allograft histologic damage progression. J Am Soc Nephrol 2005; 16:817-824.
76. Gueler F, Gwinner W, Schwarz A, Haller H. Long-term effects of acute ischemia and reperfusion injury. Kidney Int 2004; 66:523-527.
77. Erpicum P, Detry O, Weekers L, et al. Mesenchymal stromal cell therapy in conditions of renal ischaemia/reperfusion. Nephrol Dial Transplant 2014; 0:1-7. [Epub ahead of print]
78. Eltzschig HK, Eckle T. Ischemia and reperfusion- from mechanism to translation. Nat Med 2011; 17:1391-1401.
79. Bryan CF, Luger AM, Martinez J, et al. Cold ischemia time: an independent predictor of increased HLA class I antibody production after rejection of a primary cadaveric renal allograft. Transplantation 2001; 71:875-879.
80. Fuquay R, Renner B, Kulik L, et al. Renal ischemia-reperfusion injury amplifies the humoral immune response. J Am Soc Nephrol 2013; 24:1063-1072.